REGISTER BY 31ST JANUARY AND SAVE £400REGISTER BY 28TH FEBRUARY AND SAVE £200REGISTER BY 31ST MARCH AND SAVE £100

PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPWednesday 24th May 2017, Copthorne Tara Hotel, London, UK

www.pain-therapeutics.co.uk Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

ACADEMIC & GROUP DISCOUNTS AVAILABLE@SMIPHARM

#painsmi

Animal Models of Pain: A Critical Assessment8.30 - 12.30

Workshop Leader: Dr Steven G. Kamerling, Senior Research Director and Therapeutic Area Head for Pain, Infl ammation, Oncology and Cardiac Disease, Global Therapeutics Research, Zoetis

Assess the latest developments and innovations in effective and safe pain management

SMi Presents the 17th Annual Conference on...

Copthorne Tara Hotel, London, UK

Pain Therapeutics CONFERENCE:22ND - 23RD

WORKSHOP: 24TH

MAY 2017

“A very informative and interactive conference!” DELEGATE 2016

“I’ll attend this conference again if I’ll be able to” DELEGATE 2016

Sponsored by REASONS TO ATTEND: • Strategies and real case studies to minimise risk of opioid

dependence • Evaluate the translation gap with case studies from a

pre-clinical and clinical perspective • Assess the latest case studies from top pharma companies

in the multi-faceted area of pain for 2017 • Examine the use of animal models to study pain pathways

CHAIRS FOR 2017: • Prof Anthony Jones, Professor of Neuro-Rheumatology,

University of Manchester • Dr Steven Kamerling, Therapeutic Area Head for Pain,

Infl ammation and Oncology, Zoetis • Dr Joseph W. Stauffer, Chief Medical Offi cer,

Cara Therapeutics, Inc.

KEYNOTE SPEAKERS INCLUDE: • Dr Stephen Doberstein, Senior Vice President and Chief

Scientifi c Offi cer, Nektar Pharmaceuticals • Dr Iain Chessell, Head of Neuroscience, AstraZeneca • Dr Randall Stevens, Chief Medical Offi cer, Centrexion

Therapeutics Corp. • Dr Richard Butt, Chief Executive Offi cer, Apollo Therapeutics • Prof Theo Meert, Head of Global Government Grant Offi ce,

Janssen Pharmaceutica NV • Dr Thomas Klein, Associate Director Translational Science,

Mundipharma Research • Dr Tanja Ouimet, Head of Clinical Operations, Pharmaleads • Dr Narender Gavva, Scientifi c Director, Amgen • Dr Thomas Christoph, Head of Pharmacology and Biomarker

Development, Grunenthal GmbH • Dr Ian Bell, Principal Scientist, MSD, USA

Pain Therapeutics Day One | Monday 22nd May 2017 www.pain-therapeutics.co.uk

8.30 Registration & Coffee

9.00 Chairman’s Session Opening Remarks Prof Anthony Jones, Professor of Neuro-Rheumatology, University of Manchester

OPENING KEYNOTE ADDRESS9.10 Challenges in the development of novel pain treatment

options • Confl icts in pain research • Confl icts in economic value • Confl icts in using compound • Opioid addiction Prof Theo Meert, Head of Global Government Grant Offi ce,

Janssen Pharmaceutica NV

KEYNOTE ADDRESS9.50 CGRP receptor antagonists for the treatment of migraine Migraine is a highly disabling disorder that poses a signifi cant

societal burden. Blockade of the CGRP receptor has been shown to be effective for both acute and preventive treatment of this neurovascular headache. This presentation will describe the most recent clinical candidates discovered at MSD

• CGRP receptor antagonists have demonstrated clinical effi cacy for acute treatment of migraine

• Strategy for reducing the risk of hepatotoxicity • Discovery and profi le of the current clinical candidates Dr Ian Bell, Principal Scientist, MSD, USA

10.30 Morning Coffee

11.00 The utility of early pharmacodynamics testing in pain drug development

• Failure rate of new analgesic compounds in phase II is notoriously high. Determining pharmacodynamic effects of novel drugs in healthy subjects prior to moving to patient studies can reduce risk by proving pharmacology and aiding in dose selection

• We performed three studies with three different potentially analgesic compounds in healthy subjects, using the PainCart, a multimodal pain test battery

• Each of the studies had a randomized 4- or 5-way cross-over design and was double-blind, placebo- and active comparator controlled

• The compounds that were tested included an �2/3 subunit selective GABA-A receptor agonist, a pan-Trk inhibitor, and a selective Nav1.7 sodium channel blocker. The positive controls were pregabalin and ibuprofen

• The studies were performed in parallel to phase II studies in patients and aimed to test the correlation between effi cacy of the compounds in evoked pain test models and effi cacy in patients with clinical pain

• Results of each of the three PainCart studies will be presented at the meeting

Dr Geert Jan Groeneveld, Research Director, Centre for Human Drug Research

Dr Richard Butt, Chief Executive Offi cer, Apollo Therapeutics

11.40 Patient stratifi cation based on somatosensory phenotyping: Implications for mechanism-based pain treatment and drug development

• Quantitative Sensory Testing (QST) • Interpretation of sensory profi les • Correlation between sensory profi les and treatment

effi cacy Dr Thomas Klein, Associate Director Translational Science,

Mundipharma Research

12.20 Networking Lunch

1.25 Brain mechanisms of vulnerability and resilience to pain: Who controls the magic?

• What happens in the brain when we are in pain? • What makes us more or less susceptible to pain? • How can we use this information to understand current

treatments and develop new brain-based therapies? Prof Anthony Jones, Professor of Neuro-Rheumatology,

University of Manchester

2.05 Chairman’s Session Opening Remarks Dr Steven Kamerling, Therapeutic Area Head for Pain,

Infl ammation and Oncology, Zoetis

KEYNOTE ADDRESS2.10 How veterinary trials inform human analgesic drug

development The assessment and alleviation of pain in companion animals is

an important component of veterinary medicine. Companion dogs spontaneously develop painful diseases similar to those in humans, such as osteoarthritis, cancer, and neuropathies. An increasing number of human pharmaceutical companies are turning to veterinary medicine for proof of concept studies to assess novel drug targets

• What are the similarities in pain states between dogs and humans and how are they assessed?

• What veterinary trials have been conducted on novel pain therapies and how have they informed human drug development?

• What advantages and disadvantages do veterinary trials have compared to preclinical assessment in rodent pain models?

Dr Steven Kamerling, Therapeutic Area Head for Pain, Infl ammation and Oncology, Zoetis

2.50 Afternoon Tea

3.20 Translational pain research A growing number of clinical candidates for the treatment

of pain failed in clinical POC. How does the industry react to decrease attrition?

• Potential and limitations of animal studies • From animals to human tissue • How to improve our screening tools Dr Thomas Christoph, Head of Pharmacology and Biomarker

Development, Grunenthal GmbH

4.00 Improving the translatability of neurophysiological pharmacodynamic biomarkers in pain pathways

• The need for translatable pharmacodynamic biomarkers in drug discovery

• Neurophysiological biomarkers for drug targets in different compartments of the pain pathways; a preclinical perspective

• How a new IMI2 call aims to clinically validate these neurophysiological biomarkers in healthy subjects

Dr Keith Phillips, Senior Research Scientist, Lilly UK

4.40 Chairman’s Closing Remarks and Close of Day One

DRUG DEVELOPMENT, FORMULATION & MECHANISMSTRANSLATIONAL APPROACH & ANIMAL MODELS

Register online at www.pain-therapeutics.co.uk

SPONSORSHIP AND EXHIBITION OPPORTUNITIESSMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking

opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specifi c to your industry. Should you wish to join the increasing number of companies benefi ting from sponsoring our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

Since 1987, CHDR has developed into a unique research organisation specialising in early phase studies which combines knowledge and academic collaborations with operational excellence in clinical trial services. CHDR’s strong track record in analgesic and pain research allows us to offer an effi cient route towards proof of concept in patients. www.chdr.nl

Sponsored by Offi cial Media Partner: Offi cial Publications

Pain Therapeuticswww.pain-therapeutics.co.uk Day Two | Tuesday 23rd May 2017

OPIOID ADDICTION

08.30 Registration & Coffee

09.00 Chairman’s Opening Remarks Dr Joseph Stauffer, Chief Medical Offi cer,

Cara Therapeutics, Inc.

OPENING ADDRESS9.10 Kappa Opioid Receptor Agonists (KORA’S): A novel

approach to managing acute and chronic pain • Review of the kappa opioid class • Human abuse liability data of CR845 a novel KORA • Post-operative and chronic pain data of CR845 Dr Joseph Stauffer, Chief Medical Offi cer,

Cara Therapeutics, Inc.

KEYNOTE ADDRESS9.50 NKTR-181: Separating analgesia from euphoria in a novel

opioid agonist for chronic pain Traditional mu-opioid agonists can have excellent analgesic

properties, but are typically associated with high abuse liability that can lead to addiction and dependence. Recent research has associated the rate of molecular entry across the blood brain barrier with increased abuse liability in preclinical species. Novel opioids that have greatly reduced rates of entry into the CNS separate the euphorigenic effects from the analgesic effects of CNS receptor engagement, raising the prospect of an inherently low-abuse liability opioid analgesic, independent of formulation or route of administration.

• Drugs of abuse: Relationship of brain entry rate to euphoria and reinforcing behavior

• Engineering brain entry rate of MOR agonists to reduce euphoria and abuse liability

• Preclinical analysis of brain transport rate, dopamine release, and reinforcing behavior

• Clinical analysis of human abuse liability of NKTR-181, a novel opioid agonist with inherently slow CNS entry Dr Stephen Doberstein, Senior Vice President and Chief

Scientifi c Offi cer, Nektar Pharmaceuticals

10.30 Morning Coffee

11.00 Enhancing endogenous opioid concentrations as a novel treatment for severe pain

Enkephalins are highly potent opioids produced and released endogenously at the site of a painful stimulus. As they are rapidly degraded by two metalloproteases, aminopeptidase N (APN) and Neprilysin (NEP), the actions these opioid peptides are very short lived. Animal studies have shown that inhibiting the breakdown of enkephalins by inhibiting both NEP and APN produces signifi cant analgesia. PL37 and PL265 are the fi rst Dual ENKephalinase Inhibitors (DENKIs) to reach the clinic

• MoA of the Dual ENKephalinase Inhibitors (DENKIs) • Clinical results obtained with PL37 • Clinical development of PL265 Dr Tanja Ouimet, Head of Clinical Operations, Pharmaleads

KEYNOTE ADDRESS11.40 Exploiting synergy in the neurotrophin pathway to provide

analgesia • Opportunity to expand effi cacy of anti-NGFs to

neuropathic pain • Unexpected synergy between blockade of NGF and

infl ammatory pathways • Signifi cant analgesia in preclinical models at suppression

of NGF <10 % Dr Iain Chessell, Head of Neuroscience, AstraZeneca

12.20 Networking Lunch

KEYNOTE ADDRESS1.30 Considerations on advancing a novel analgesic pipeline The current set of analgesics available to patients has been

inadequate to manage chronic pain. The inadequacies stem from both insuffi cient effi cacy, as well as substantial risks in these analgesics use for chronic pain. Development of novel, non-opioid analgesics that match the safety and effi cacy requirements of indications improves the drugs’ utility and likelihood of technical success

• Risk: Benefi t in matching drug and target to appropriate indications and populations

• Utility of Big Data analytics in identifying indications for novel analgesics

• Case Study of CNTX-4975 development in Morton’s Neuroma and Knee Osteoarthritis

Dr Randall Stevens, Chief Medical Offi cer, Centrexion Therapeutics Corp.

2.10 Using patient reported outcome measures to improve the management of pain (PROMs)

• Use of PROMs in patient management and clinical trials in pain

• Correlation of baseline characteristics and PROMs for specifi c pain conditions- available evidence

• New IMI2 call will help enhance use of PROMs in the management of different pain conditions as well as in pain research

Dr Shaloo Pandhi, Global Program Medical Director, Novartis

2.50 Afternoon Tea

3.20 Drug development to patients: What does the road look like? • Therapy areas and patient selection • Market and marketing • Legislation and access Dr Karin Hygge Blakeman, Head of Medical Affairs Nordics,

Grunenthal Sweden AB 4.00 Potassium channels as pain and migraine targets:

Challenges and path forward • Nociceptive pathways • K+ channels and pain signalling • Voltage-gated K+ channels • Two pore domain channels Dr Narender Gavva, Scientifi c Director, Amgen

4.40 Chairman’s Closing Remarks and Close of Day Two

THERAPEUTIC APPROACHES AND MODELS

Register online at www.pain-therapeutics.co.uk Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

MARKETING OPPORTUNITIESWant to know how you can get involved? Interested in promoting your services to this market?

Contact Teri Arri, SMi Marketing on +44 (0) 207 827 6162 or email: tarri@smi-online.co.uk

Offi cial Publications Supported by

Animal Models of Pain: A Critical Assessment

Overview of the workshop:The purpose of this workshop is to educate the audience on the various animal models used to evaluate analgesic drugs. Strengths, weakness and the clinical relevance of the models will be described with an emphasis on pain associated with osteoarthritis. Pain will be defi ned as a phenomenon and with regard to site, modality, electrophysiology, neuronal plasticity and affective state. The utility of pain biomarkers and their relationship to PK/PD will be introduced along with relevant drug targets and mechanisms.

Why should you attend this workshop:• To understand the pain phenomenon from a molecular to a

clinical perspective • To understand what pain models appropriate for the drug

target and mechanism of interest• To make informed decisions on which models to invest in for

effi cacy proof of concept for novel analgesic drugs• If you are particularly interested in how best to assess the

effi cacy and safety of a novel analgesic for the treatment of osteoarthritic pain

Programme08.30 Registration & Coffee09.00 Opening remarks and introductions 09.10 Defi ning the pain phenomenon • Understanding pain associated with anatomical

site, disease pathology, and its duration • Clinical pain states, the role of infl ammation, pain

mediators • Peripheral and central sensitization09.50 Animal models and pain • Models of spontaneous and evoked pain • Models of neuropathic, visceral, and cancer pain • Models of affective pain behaviours • Drugs active in these models; why and why not10.30 Morning Coffee11.00 Focus on osteoarthritis pain • Models of pain associated with osteoarthritis • Interpretation of effi cacy and safety data • Relevance of animal models to human clinical

pain states • Analgesics that translate between human and

animal pain models 11.40 Current approach to use pain biomarkers • Pain biomarkers and their relationship to disease • Pain biomarkers and the effects of analgesics: PK/PD • Relevance of pain biomarkers in experimental

and human clinical pain states 12.20 Closing remarks12.30 End of workshop

About the workshop leader:Steve is a Registered Pharmacist and received his Pharmacy degree from Drake University. He then pursued graduate studies in Pharmacology and received a PhD from the College of Medicine at the University of Illinois. Steve became a postdoctoral fellow in Pharmacology at the University of Kentucky, College of Medicine from, later becoming a Research Associate in Veterinary Sciences. His research at the time focused on in vivo neuropharmacology of pain transmission and opioid and nicotine pharmacology. Subsequently, Steve joined the faculty of the School of Veterinary Medicine at Louisiana State University and achieved the rank of Endowed Professor at the time of his departure. He subsequently joined the Pharmacia & Upjohn Company (later becoming Pfi zer then Zoetis) to pursue a career in drug discovery and has continued in that capacity since 1999. Steve is currently Therapeutic Area Head of Pain & Infl ammation, Oncology, Cardiac Disease and Oncology. Steve’s research interests include animal models of pain, arthritis, infl ammation, heart disease and the pharmacology of novel analgesics, NSAIDs, opioids and sedatives. He has also been active in evaluating novel, molecularly targeted therapeutics in spontaneous canine neoplasias, from a translational medicine perspective. Steve enjoys playing jazz guitar and singing in his free time.

About the organisation:Zoetis discovers, develops, manufactures and commercializes a diverse portfolio of animal health medicines and vaccines designed to meet the real-world needs of veterinarians and the livestock farmers and companion animal owners they support. With its more than 60 years of experience in animal health, Zoetis generated $4.8 billion in revenue in 2015 and sells products in over 100 countries. There are approximately 9000 Zoetis colleagues, with approximately 1,050 in Research and Development, and approximately 2800 fi eld force members. www.zoetis.com

Workshop Leader: Dr Steven G. Kamerling, Senior Research Director and Therapeutic Area Head

for Pain, Infl ammation, Oncology and Cardiac Disease, Global Therapeutics Research, Zoetis

HALF-DAY POST-CONFERENCE WORKSHOPWednesday 24th May 2017

08.30 – 12.30Copthorne Tara Hotel, London, UK

SCIENTIFIC ADVISORY BOARD FOR 2017

Steven G. Kamerling, RPh, PhD, Research Fellow and Therapeutic Area Head for Pain, Infl ammation and Oncology, Global Therapeutics Research, Veterinary Medicine Research

and Development, Zoetis

Steve joined the Pharmacia & Upjohn Company (subsequently, Pfi zer then Zoetis) in 1999 to pursue a career in drug discovery and has continued in that capacity ever since. Steve is currently Therapeutic Area Head of Pain & Infl ammation, Cardiac Disease and Oncology. Steve’s research interests include large animal models of pain, arthritis, infl ammation, heart disease and the pharmacology of NSAIDs, opioids and sedatives. He has also been active in evaluating novel, molecularly targeted therapeutics in spontaneous canine neoplasias, from a translational medicine perspective.

Joseph W. Stauffer, DO, MBA, Chief Medical Offi cer, Cara Therapeutics, Inc.

Joe is also the Founder of Alta Life Sciences, LLC, a boutique pharmaceutical/investment consulting fi rm. He is a 2002 founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). In 2011, under the FDA’s Critical Path Initiative, this collaboration became an offi cial public-private partnership between pharma, FDA, NIH, academia and patient advocacy associations. In 2005 he served as an expert member of the FDA/Mayo Clinic Working group on Patient Reported Outcomes and co-authored the supportive paper (Value in Health, Nov/Dec 2007) on validation of self-reported outcome measures. In 2007 he was named one of the “100 Most Inspiring People” by PharmaVOICE magazine. In 2011 he was selected as a Board member of the American Academy of Pain Medicine Foundation. In 2014 he was appointed to the Board of Directors of TrialScope, a provider of technology enhanced clinical trial solutions and services.

Professor Anthony Jones, Professor of Neuro-Rheumatology, University of Manchester

Anthony Jones is professor of Neuro-rheumatology at Manchester University and leads the Human Pain Research Group. He is a consultant rheumatologist at Salford Royal Foundation Trust. He has established one of the fi rst multidisciplinary infl ammatory arthritis clinics in the North West for patients with complex needs. Over the last twenty years he has used a number of functional brain imaging techniques to understand the normal and abnormal mechanisms of pain perception. He also leads the International Association for the Study of Pain Musculoskeletal Pain Taskforce, and has led the development of National and International Guidelines on the Integrated Management of Musculoskeletal Pain (jointly sponsored by the BSR and the IASP). His main current goals are to use the current understanding of pain perception to encourage more rational use of current therapies and to develop new mechanisms-based treatments for pain.

Pain Therapeutics www.pain-therapeutics.co.uk

Register online at www.pain-therapeutics.co.uk

Alternatively fax your registration to +44 (0)870 9090 712

or call +44 (0)870 9090 711

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Company VAT Number:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Mobile:

Switchboard:

Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefi ngs we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifi cally to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-207 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment:

□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.

Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder’s Name:

Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.

Card Billing Address (If different from above):

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk

EARLY BIRD DISCOUNT

□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: events@smi-online.co.uk or fax +44 (0) 870 9090 712

I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total□ Access to the conference documentation

on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00

(or only £300 if ordered with the Document Portal)

Unique Reference Number

Our Reference LVP-207

DELEGATE DETAILS

Terms and Conditions of Booking

PAYMENT

VAT

CONFERENCE PRICES

DOCUMENTATION

VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SY London

PAIN THERAPEUTICS Conference: Monday 22nd & Tuesday 23rd May 2017, Copthorne Tara Hotel, London, UK Workshop: Wednesday 24th May 2017, London, UK

4 WAYS TO REGISTERwww.pain-therapeutics.co.uk

FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK

□ Book by 31st January to receive £400 off the conference price□ Book by 28th February to receive £200 off the conference price□ Book by 31st March to receive £100 off the conference price

I would like to attend: (Please tick as appropriate) Fee Total

□ Conference & Workshop £2098.00 + VAT £2517.60□ Conference only £1499.00 + VAT £1798.80□ Workshop only £599.00 + VAT £718.80

PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional

literature to all conference attendees £999.00 + VAT £1198.80

The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.